Vandana Sachdev

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2954313/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. New England Journal of Medicine, 2004, 350, 886-895.	13.9	1,172
2	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	3.8	619
3	Phenotype and Course of Hutchinson–Gilford Progeria Syndrome. New England Journal of Medicine, 2008, 358, 592-604.	13.9	610
4	Pulmonary Nontuberculous Mycobacterial Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1066-1074.	2.5	356
5	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. Journal of the American College of Cardiology, 2007, 49, 472-479.	1.2	265
6	Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clinical Cancer Research, 2006, 12, 3762-3773.	3.2	237
7	The ClinSeq Project: Piloting large-scale genome sequencing for research in genomic medicine. Genome Research, 2009, 19, 1665-1674.	2.4	236
8	Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1272-1279.	2.5	227
9	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	0.6	210
10	Cardiovascular Abnormalities in Sickle Cell Disease. Journal of the American College of Cardiology, 2012, 59, 1123-1133.	1.2	205
11	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology, 2005, 130, 445-453.	1.2	192
12	Pediatric Fabry Disease. Pediatrics, 2005, 115, e344-e355.	1.0	171
13	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	1.7	170
14	N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2006, 296, 310.	3.8	169
15	A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Molecular Genetics and Metabolism, 2011, 103, 307-314.	0.5	167
16	Aortic Valve Disease in Turner Syndrome. Journal of the American College of Cardiology, 2008, 51, 1904-1909.	1.2	148
17	Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic <i>Trypanosoma cruzi</i> –Seropositive Former Blood Donors. Circulation, 2013, 127, 1105-1115.	1.6	145
18	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124

VANDANA SACHDEV

#	Article	IF	CITATIONS
19	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 840-847.	2.5	114
20	Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine <i>Versus</i> Levothyroxine. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3466-3474.	1.8	110
21	Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. British Journal of Haematology, 2007, 136, 319-325.	1.2	109
22	Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American Journal of Hematology, 2008, 83, 15-18.	2.0	108
23	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	1.1	107
24	Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American Journal of Hematology, 2008, 83, 485-490.	2.0	93
25	Cerebellar Ataxia, Seizures, Premature Death, and Cardiac Abnormalities in Mice with Targeted Disruption of the Cacna2d2 Gene. American Journal of Pathology, 2004, 165, 1007-1018.	1.9	88
26	Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy. American Heart Journal, 2005, 149, 730-736.	1.2	80
27	Pulmonary Artery Pressure in Lymphangioleiomyomatosis. Chest, 2007, 132, 1573-1578.	0.4	77
28	Familial eosinophilia: a benign disorder?. Blood, 2004, 103, 4050-4055.	0.6	71
29	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology, 2009, 147, 737-743.	1.2	69
30	Technology preview: Xâ€ray fused with magnetic resonance during invasive cardiovascular procedures. Catheterization and Cardiovascular Interventions, 2007, 70, 773-782.	0.7	62
31	Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. American Journal of Hematology, 2008, 83, 6-14.	2.0	60
32	Tenascin-X Haploinsufficiency Associated with Ehlers-Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E379-E387.	1.8	59
33	Electrocardiographic Abnormalities in Trypanosoma cruzi Seropositive and Seronegative Former Blood Donors. PLoS Neglected Tropical Diseases, 2013, 7, e2078.	1.3	57
34	Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1143-E1152.	1.8	51
35	Diastolic dysfunction in sickle cell. Blood, 2010, 116, 1-2.	0.6	48
36	Direct injection of autologous mesenchymal stromal cells improves myocardial function. Biochemical and Biophysical Research Communications, 2009, 390, 902-907.	1.0	44

VANDANA SACHDEV

#	Article	IF	CITATIONS
37	Increased Pulmonary Pressures and Myocardial Wall Stress in Children with Severe Malaria. Journal of Infectious Diseases, 2010, 202, 791-800.	1.9	44
38	Spectrum of Aortic Valve Abnormalities Associated With Aortic Dilation Across Age Groups in Turner Syndrome. Circulation: Cardiovascular Imaging, 2013, 6, 1018-1023.	1.3	42
39	Aortic stenosis and vascular calcifications in alkaptonuria. Molecular Genetics and Metabolism, 2012, 105, 198-202.	0.5	40
40	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	1.7	40
41	Growth Hormone Treatment and Left Ventricular Dimensions in Turner Syndrome. Journal of Pediatrics, 2007, 150, 587-591.	0.9	37
42	Significance of Left Atrial Contractile Function in Asymptomatic Subjects With Hereditary Hemochromatosis. American Journal of Cardiology, 2006, 98, 954-959.	0.7	36
43	Effect of Statin Therapy on Survival in Patients With Nonischemic Dilated Cardiomyopathy (from the) Tj ETQq1 1	0.784314 0.7	• rggT /Overld
44	Echocardiographic Findings in the PANDAS Subgroup. Pediatrics, 2004, 114, e748-e751.	1.0	32
45	Cardiovascular complications of sickle cell disease. Trends in Cardiovascular Medicine, 2021, 31, 187-193.	2.3	32
46	Characteristics of cardiomyopathy in Alström syndrome: Prospective single-center data on 38 patients. Molecular Genetics and Metabolism, 2017, 121, 336-343.	0.5	31
47	Does Oxidative Stress Modulate Left Ventricular Diastolic Function in Asymptomatic Subjects with Hereditary Hemochromatosis?. Echocardiography, 2009, 26, 1153-1158.	0.3	29
48	Priorities for Patient entered Research in Valvular Heart Disease: A Report From the National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association, 2020, 9, e015975.	1.6	29
49	Left Ventricular Systolic Function During Stress Echocardiography Exercise in Subjects With Asymptomatic Hereditary Hemochromatosis. American Journal of Cardiology, 2006, 98, 694-698.	0.7	27
50	Implementing the National Heart, Lung, and Blood Institute's Strategic Vision in the Division of Cardiovascular Sciences. Circulation Research, 2019, 124, 491-497.	2.0	27
51	Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHLR200W mutation (Chuvash polycythemia). Haematologica, 2012, 97, 193-200.	1.7	26
52	Myocardial Strain Decreases with Increasing Transmurality of Infarction: A Doppler Echocardiographic and Magnetic Resonance Correlation Study. Journal of the American Society of Echocardiography, 2006, 19, 34-39.	1.2	23
53	Are Echocardiography and CMR Really Discordant in Mitral Regurgitation?. JACC: Cardiovascular Imaging, 2017, 10, 823-824.	2.3	22
54	Pragmatic Design of Randomized Clinical Trials for HeartÂFailure. JACC: Heart Failure, 2021, 9, 325-335.	1.9	22

VANDANA SACHDEV

#	Article	IF	CITATIONS
55	Quantification of aortic regurgitation by real-time 3-dimensional echocardiography in a chronic animal model: Computation of aortic regurgitant volume as the difference between left and right ventricular stroke volumes. Journal of the American Society of Echocardiography, 2001, 14, 1112-1118.	1.2	18
56	Pleiotropic Effect of Lovastatin, With and Without Cholestyramine, in the Post Coronary Artery Bypass Graft (Post CABG) Trial. American Journal of Cardiology, 2008, 102, 1023-1027.	0.7	18
57	Skeletal and myocardial microvascular blood flow in hydroxycarbamideâ€ŧreated patients with sickle cell disease. British Journal of Haematology, 2017, 179, 648-656.	1.2	18
58	Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization. Annals of Thoracic Surgery, 2020, 109, 1142-1149.	0.7	15
59	Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Advances, 2019, 3, 2816-2824.	2.5	14
60	Case study and review: Treatment of tricuspid prosthetic valve thrombosis. International Journal of Cardiology, 2012, 162, 14-19.	0.8	12
61	Effect of Extended-Release Niacin on Serum Lipids and on Endothelial Function in Adults With Sickle Cell Anemia and Low High-Density Lipoprotein Cholesterol Levels. American Journal of Cardiology, 2013, 112, 1499-1504.	0.7	10
62	Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease. Haematologica, 2016, 101, e40-e43.	1.7	10
63	A phenotypic risk score for predicting mortality in sickle cell disease. British Journal of Haematology, 2021, 192, 932-941.	1.2	9
64	Is Functional Capacity Related to Left Atrial Contractile Function in Nonobstructive Hypertrophic Cardiomyopathy?. Congestive Heart Failure, 2005, 11, 234-240.	2.0	8
65	FOS expression in blood as a LDL-independent marker of statin treatment. Atherosclerosis, 2010, 212, 567-570.	0.4	7
66	Use of sacubitril/valsartan in acute decompensated heart failure: a case report. ESC Heart Failure, 2018, 5, 184-188.	1.4	7
67	Atorvastatin Therapy Restores Nitric Oxide-Dependent Vascular Responsiveness in Patients with Sickle Cell Disease Blood, 2004, 104, 239-239.	0.6	7
68	Growth hormone and risk for cardiac tumors in Carney complex. Endocrine-Related Cancer, 2016, 23, 739-746.	1.6	6
69	Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease Blood, 2004, 104, 1669-1669.	0.6	6
70	The Sickle Cell-Pulmonary Hypertension Screening Study: ECHO Findings at Two-Years of Follow Up Blood, 2005, 106, 314-314.	0.6	6
71	Effect of a Histone Deacetylase Inhibitor on Human Cardiac Mass. Cardiovascular Drugs and Therapy, 2005, 19, 89-90.	1.3	5
72	Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4327-e4339.	1.8	5

#	Article	IF	CITATIONS
73	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease Blood, 2005, 106, 206-206.	0.6	4
74	Changes in Left Ventricular Diastolic Function of Asymptomatic Hereditary Hemochromatosis Subjects During Five Years of Follow-Up. American Journal of Cardiology, 2011, 108, 1796-1800.	0.7	2
75	Low-dose, short course alteplase treatment of submassive pulmonary embolism. Blood Coagulation and Fibrinolysis, 2018, 29, 701-707.	0.5	2
76	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	0.6	2
77	Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. Blood, 2012, 120, 3240-3240.	0.6	1
78	The Authors Reply:. JACC: Cardiovascular Imaging, 2017, 10, 606.	2.3	0